Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | F12 | P00748 | 4/20 | 0.46 |
| ▸ | MGAM | O43451 | 3/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SI | P14410 | 3/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052652 | 0.78 | PTGDR2 (0.47) | KMT2AHPGDLMNAALDH1A1KDM4E | |
| SCHEMBL12648233 | 0.66 | F12 (0.54) | F12MGAMAMY1AGAASI | |
| SCHEMBL4052629 | 0.66 | GAPDH (0.46) | KMT2AHPGDLMNAALDH1A1MAPT | |
| SCHEMBL426868 | 0.66 | F12 (0.53) | KMT2ANPSR1F12MGAMAMY1A | |
| SCHEMBL18286215 | 0.65 | MGAM (0.59) | KMT2ANPSR1F12MGAMAMY1A | |
| SCHEMBL462692 | 0.65 | NPSR1 (0.60) | KMT2ANPSR1F12MGAMAMY1A | |
| SCHEMBL462691 | 0.65 | NPSR1 (0.60) | KMT2ANPSR1F12MGAMAMY1A | |
| SCHEMBL12648420 | 0.65 | F12 (0.53) | KMT2ANPSR1F12MGAMAMY1A | |
| SCHEMBL3130159 | 0.64 | GAA (0.59) | KMT2AF12MGAMAMY1AGAA | |
| SCHEMBL13134139 | 0.64 | GAA (0.58) | KMT2ANPSR1F12MGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| EP-2024371-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134434-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | KMT2A 2400/4885NPSR1 845/4885F12 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.